Evaluation of Ionic Liquids and Ionic Liquids Active Pharmaceutical Ingredients Inhibition in Elastase Enzyme Activity

Fátima A. R. Mota 1,2, Sarah A. P. Pereira 1, André R. T. S. Araujo 1,2* and M. Lúcia M. F. S. Saraiva 1,*

1 LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, Porto University, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; fatimaamota@gmail.com (F.A.R.M.); sarah.pp@hotmail.com (S.A.P.P.); andrearaujo@ipg.pt (A.R.T.S.A.)
2 Unidade de Investigação para o Desenvolvimento do Interior, Instituto Politécnico da Guarda, Av. Dr. Francisco de Sá Carneiro, No. 50, 6300-559 Guarda, Portugal
* Correspondence: lsaraiva@ff.up.pt; Tel.: +351-220428674; Fax: +351-226093483

Abstract: Human neutrophil elastase (HNE) is used as diagnostic biomarker for inflammation/infection. In this work, 10 ionic liquids (ILs) and 11 ionic liquids active pharmaceutical ingredients (ILs-APIs) were tested to evaluate the inhibition effect on the activity of porcine pancreatic elastase enzyme, frequently employed as a model for HNE. The insertion of ionic liquids in some drugs is useful, as the insertion of ILs with inhibitory capacity will also slow down all processes in which this enzyme is involved. Therefore, a spectrophotometric method was performed to the determination of EC50 values of the compounds tested. EC50 values of 124 ± 4 mM to 289 ± 11 mM were obtained, with the most toxic IL for elastase being tetrabutylammonium acetate and the least toxic 1-butyl-3-methylimidazolium acetate. Moreover, sodium salicylate (raw material) presented the lower and benzethonium bistriflimide the higher EC50 when compared with all the IL-APIs tested. This work provides significant information about the effect of the studied IL and IL-APIs in elastase enzyme activity.

Keywords: ionic liquids; ionic liquids active pharmaceutical ingredients; enzyme activity; elastase; inhibition

1. Introduction

Human neutrophil elastase enzyme (HNE) is one of the most abundant neutral proteases and is produced by neutrophilic granulocytes [1]. The neutrophilic granulocyte is the first nucleated cell to infiltrate the wound bed after the integrity of the skin has been disrupted.

In inflammatory sites, there are massive and constant infiltrations of polymorphonuclear neutrophils (PMNs) and the enzyme HNE is abundantly released into the intracellular space, activating pro inflammatory mediators and recruiting more neutrophils [2–4]. HNE is able to degrade a variety of structural and functional proteins deposited in wounds such as collagen and fibronectin, as well as key growth factors such as tumor necrosis factor α (TNF-α) [1,5]. However, the excessive production of HNE and other proteolytic enzymes by PMN granulocytes leads to extensive pathological tissue destruction in a number of disorders, including delayed and chronic wound healing [1].

Wound infection is a severe complication during wound healing causing diagnostic and therapeutic problems [1,6]. The infection is characterized by excessive neutrophil stimulation, resulting in the release of proteolytic enzymes such as HNE in plasma [7,8]. HNE has a high activity in wound healing only for a few days. Thus, in non-healing wounds, the activity of this enzyme remains high for very long time, leading to the degradation of the reconstituted tissue and often results in wound infection. This enzyme
is found since the infection begins, so its activity can be used as a diagnostic marker for the detection of wound inflammation and infection [1,9].

Since elevated HNE levels are described at the very beginning of infection, allows chronic wounds to be treated early before obvious clinical signs of infection are present. Measurement of serum, plasma and urinary elastase is often used as an indicator of the severity of inflammatory disease. However, the presence of neutrophilic enzymes can also be measured in wound fluid, providing early warning of wound infection [1].

As this is a human enzyme present since the onset of infections and inflammation, it is favorable to develop methods to inhibit it preventing the progression to more severe states of infection or inflammation.

Ionic liquids (ILs) are defined as organic salts formed by cations and anions with a melting point below 100 °C and they present interestingly physical properties such as extremely low vapor pressure, wide liquid temperature range, no inflammability, and high thermal and chemical stability [10].

There are several factors inherent in IL that can lead to enzymatic inhibition such as polarity, viscosity, nucleophilicity, hydrophobicity, enzyme dissolution, surfactant effect, anion, cation and alkylated side chain [11]. From the pharmaceutical point of the view, an IL approach in the design of new APIs appears to be appropriate as it enables the chemical manipulation of the compounds with specific objectives related to the manufacturing process, the stability of the formulations, bioavailability and eventual adverse effects [12,13]. An IL approach in the design of new APIs seem to be suitable as it allows a huge number of viable cation-anion combinations while providing singular properties inaccessible in solid salts, namely improved solubility and absence of polymorphic forms [14,15]. The research in this field has been focused mostly on the synthesis of new IL-APIs, their physico-chemical characterization and in vitro assessment of the expected pharmacological activity [16,17].

In this work, different ILs and ionic liquids active pharmaceutical ingredients (ILs-APIs) were tested to the ability to inhibit porcine elastase enzyme activity. Porcine elastase and HNE belongs to the same protease family and they present the same catalytic center, being used several times as a model protein for HNE [18].

The negative effect that ILs can have on enzyme reactions is advantageous when it is intended to inhibit enzyme activity, stability or structure. The association of ionic liquids with some drugs (ILs-APIs) or even its use as a drug is advantageous in this regard as it can have a possible healing effect by impairing elastase activity. On the other hand, ILs can be good alternatives as drug solvents as their toxicity in the human organism is usually lower than that which organic solvents can develop [11].

In order to evaluate the effect of these compounds (ILs and IL-APIs), an enzymatic reaction based on the conversion of the substrate N-succinyl-Ala-Ala-Ala-p-nitroaniline to succinyl-Ala-Ala-Ala and p-nitroaniline by the enzyme elastase was performed. The enzyme activity is determined by the formation of p-nitroaniline, the chromogenic compound resulted from the reaction. Substrate degradation was continuously monitored in the spectrophotometer by measuring increasing absorbance at 405 nm.

2. Results and Discussion

The methodology followed to evaluate elastase enzyme activity and its subsequent inhibition by ILs and IL-APIs was optimized regarding the temperature, reaction time, substrate concentration, and enzyme volume and concentration, as described in the Materials and Methods.

2.1. Evaluation of Ionic Liquids Inhibition in Elastase Enzyme Activity

After establishing the conditions of the enzyme inhibition assay, the effect of ten commercially available ILs on Elastase activity was evaluated. The tested compounds showed variable chemical structures and incorporated different structural elements, allowing the identification of possible fractions that could act as toxophores (Table 1).
Table 1. Results of elastase inhibition by ILs expressed as EC<sub>50</sub>.

| Ionic Liquid (IL)                                    | IL Abbreviation | Molecular Weight (g mol<sup>-1</sup>) | EC<sub>50</sub> (mM) ± SD<sup>(1)</sup> | Confidence Interval |
|-----------------------------------------------------|-----------------|---------------------------------------|----------------------------------------|---------------------|
| MeOSuc-Ala-Ala-Pro-Val-chloromethylketone            | -               | 503.0                                 | 0.47 ± 0.05                            | ±0.47               |
| 1-Butyl-3-methylimidazolium tetrafluoroborate       | [bmim] BF<sub>4</sub> | 226.0                                 | 208 ± 8                                | ±70                 |
| 1-Ethyl-3-methylimidazolium tetrafluoroborate       | [emim] BF<sub>4</sub> | 197.9                                 | 201 ± 51                               | ±457                |
| 1-Butyl-3-methylimidazolium chloride                | [bmim] Cl       | 174.7                                 | 248 ± 49                               | ±441                |
| 1-Ethyl-3-methylimidazolium trifluoromethanesulfonate | [emim] Tfms      | 260.2                                 | 239 ± 5                                | ±46                 |
| 1-Butyl-1-methylpyrrolidinium chloride              | [bmpyr] Cl      | 177.7                                 | 194 ± 1                                | ±12                 |
| 1-Butyl-4-methylpyridinium tetrafluoroborate        | [bmpy] BF<sub>4</sub> | 237.0                                 | 239 ± 3                                | ±30                 |
| Tetrabutylammonium acetate                         | [tba] Ac        | 301.5                                 | 176 ± 6                                | ±55                 |
| Tetrabutylammonium chloride                        | [tba] Cl        | 277.9                                 | 233 ± 24                               | ±216                |
| Tetrabutylphosphonium methanesulfonate              | [Tbph] Ms       | 354.5                                 | 229.9 ± 0.6                            | ±5                  |
| 1-Butyl-3-methylimidazolium acetate                | [bmim] Ac       | 198.3                                 | 289 ± 22                               | ±200                |

<sup>(1)</sup> Standard deviation.

The enzyme activity was studied in aqueous medium and ILs were prepared daily in aqueous solutions with increasing concentrations.

The EC<sub>50</sub> values for each IL were calculated as the inhibitory concentration causing a 50% decrease in Elastase activity [19]. The EC<sub>50</sub> values were automatically calculated, using GraphPad prism8 software.

The studied ILs, and the respective calculated EC<sub>50</sub> values are shown in Table 1, and the inhibition profile of each one is represented graphically in Figure 1.

Looking to the results, we can conclude that the most toxic IL for elastase is tetrabutylammonium acetate and the least toxic is 1-butyl-3-methylimidazolium acetate.

ILs offer several ranges of physical and chemical properties, depending on cations and anions. These physico-chemical properties (such as polarity, hydrophobicity, viscosity, etc.) of ILs play an important role in enzyme activity and stability. For example, considering lactic dehydrogenase (LDH) enzyme, the anions influence its activity in the following order TfMs > BF<sub>4</sub> > Br > Cl [20]. According to the results, more hydrophobic ILs have more affinity to the active loop of LDH enzyme, which is the main driving force for the ILs interaction with LDH and for instance also with lipase [21].

The toxicity decrease of the ILs may be explained by a decrease in the value of the octanol–water partition coefficient (K<sub>ow</sub>) by the introduction of an oxygenated group, which results in lower lipophilicity and consequently lower toxicity. Moreover, the position of the oxygen atom in the side chain also influences the toxicity of the compound, as it causes a change in the charge distribution thorough the chain and so alterations in the hydrophobicity of the molecule and consequently its toxicity [22].
Molecules 202, 26, 200

Figure 1. Inhibition profiles of ILs in elastase assays. Subtitles: • 1-butyl-3-methylimidazolium tetrafluoroborate; ▲ 1-ethyl-3-methylimidazolium tetrafluoroborate; ▼ 1-butyl-3-methylimidazolium chloride; ♦ 1-ethyl-3-methylimidazolium trifluoromethanesulfonate; ● 1-butyl-4-methylpyridinium tetrafluoroborate; ■ tetrabutylammonium chloride; □ tetrabutylammonium acetate; △ tetrabutylphosphonium methanesulfonate; ▽ 1-butyl-3-methylimidazolium acetate; ◇ 1-butyl-3-methylpyrrolidinium-chloride.

Furthermore, there are several factors that can interfere with the toxicity of an IL, such as the length of the side chain of alkyl cations, the presence of a functionalized side chain in the cation, the anionic portion and the cationic portion of the IL.

The anion of IL impacts the enzyme stability and activity through its ability to form hydrogen bonds and nucleophilicity properties, as demonstrated by several groups. What is generally observed is that an anion with a high hydrogen bonding capacity interacts strongly with the enzyme, causing a conformational change in the structure and affecting its activity [23].

Thus, it was important to evaluate the influence of different anions on the activity of the enzyme elastase, using tetrafluoroborate (BF$_4$), chloride (Cl), trifluoromethanesulfonate (Tfms) and acetate (Ac) nuclei. So, we can compare ILs with different anions and cations to understand which are the most toxic for this enzyme and how it is influenced by them.

Comparing the ILs [bmim] BF$_4$ (EC$_{50}$ = 208 ± 8 mM), [bmim] Cl (EC$_{50}$ = 248 ± 49 mM), and [bmim] Ac (EC$_{50}$ = 289 ± 22 mM), we can conclude that the BF$_4$ anion is the most toxic for the elastase enzyme since it has a lower EC$_{50}$ value. Lower EC$_{50}$ values were observed for ILs with the BF4 anion such as ([bmim] BF$_4$ (EC$_{50}$ = 208 ± 8 mM) and [emim] BF$_4$ (EC$_{50}$ = 201 ± 51 mM) compared to other anions. This anion has previously shown considerable negative effects on other enzymes such as acylase [24] and cytochrome C oxidase [25] and even microorganisms [23]. The nucleophilic nature alters the conformation of the enzymes...
by interacting with the positively charged sites in their structures [26]. The same happens when we compare the ionic liquids [emim] BF$_4$ (EC$_{50}$ = 201 ± 51 mM) and [emim] Tfms (EC$_{50}$ = 239 ± 5 mM), where the BF$_4$ anion is also more toxic. One possible explanation may be that molecules that contain fluorine on their composition can be hydrolysed and produce toxic hydrofluoric acid [24].

The ILs composed with the anions [emim] Tfms (EC$_{50}$ = 239 ± 5 mM) and [Tbph] Ms (EC$_{50}$ = 229.9 ± 0.6 mM) and [bmin] Ac (EC$_{50}$ = 289 ± 22 mM) revealed an insignificant effect on the enzymatic behaviour and, therefore, we conclude that the inhibition produced by these ILs is more related to the cationic group [25]. The low inhibition effect of these anions has also been verified for other enzymes and organisms: cytochrome C oxidase, carboxylesterase, catalase and V. fischeri [25]. On the other hand, the Ac anion demonstrated in another case a high inhibition, when combined with the ammonium cation [tba] Ac (EC$_{50}$ = 176 ± 6 mM). This could possibly be explained by the combination of this anion with the cation that causes high inhibition.

The studied ILs can be divided into two groups: one comprises non-aromatic ILs, based on piperidinium and pyrrolidinium, while the other comprises aromatic ILs based on imidazole and pyridinium [27].

Regarding the cationic head nucleus, it has been described by several authors as one of the main structural elements that contribute to the toxicity of ILs.

Therefore, the influence of different cations on elastase activity was assessed using the nuclei: imidazolium (im), pyridinium (pyr), pyrrolidinium (pyrr) and phosphonium (ph) [28]. The strongest inhibition was obtained with ILs containing positively charged nitrogen pyrrolidinium (bmpyrr) Cl (EC$_{50}$ = 194 ± 1 mM), imidazolium [emim] BF$_4$ (EC$_{50}$ = 201 ± 51 mM) and [bmin] BF$_4$ (EC$_{50}$ = 208 ± 8 mM) compared to other cations as [bpyrr] BF$_4$ (EC$_{50}$ = 239 ± 3 mM) and [tba] Cl (EC$_{50}$ = 233 ± 24 mM). Except [bmin] Ac (EC$_{50}$ = 289 ± 22 mM) which is a cation imidazole with the influence of an Ac anion, decreases the toxicity of the imidazolium group. This only happens for elastase, since these groups have, in general, high toxicity.

The IL with pyrrolidinium (bmpyrr) Cl (EC$_{50}$ = 194 ± 1 mM) as a cationic nucleus structure, slightly inhibited the enzyme comparing with the imidazolium analog (bmin) Cl (EC$_{50}$ = 248 ± 49 mM) [29]. The pyrrolidinium groups (bmpyrr) Cl (EC$_{50}$ = 194 ± 1 mM) showed lower EC$_{50}$ values than any IL based on aromatic imidazolium, so ILs containing pyrrolidinium groups are more toxic for elastase enzyme than the imidazolium core [25].

Among the cations that incorporate an aromatic ring, the group of the imidazolium core (bmin) BF$_4$ (EC$_{50}$ = 208 ± 8 mM) exhibited a greater toxic effect than the pyridinium (bmpy) BF$_4$ (EC$_{50}$ = 239± 3 mM). Although there is no consensus on the correlation between these two groups in the literature, a similar trend has been described for the enzyme acetylcholinesterase [25].

The effect of the length of the alkylated side chain has been discussed by several authors as responsible for an increase in toxicity [30]. This effect was named “side chain effect”, that is, the elongation of the alkylated side chain of IL increases its inhibition [19,31]. Moreover, the lipophilicity impact in the inhibition of ILs was claimed by some authors, demonstrating that the length of the alkyl side chain as the main determinant in its modulation [28,32]. So, the intrinsic inhibition of the side chain was evaluated by increasing its size (2 and 4 carbons) in the imidazolium based-ILs [25]. This is not verified in the results obtained, since if we observe the ILs (emim) BF$_4$ (EC$_{50}$ = 201 ± 51 mM) and (bmin) BF$_4$ (EC$_{50}$ = 208 ± 8 mM), we have 2 and 4 carbons respectively, and we have a more toxic effect in the IL with the lower alkylated side chain. The insertion of two more carbons in the alkyl side chain to get bmim (BF4) was not enough to influence the toxicity of the IL. In this case, probably the lipophilicity of this two ILs is relatively low and there are other factors leading the potential inhibition of these compounds as a better accessibility to the active center of the enzyme.

Despite the differences between the EC$_{50}$ being slight, this can be justified, considering that it has already been described for other enzymes, such as acylase, that the harmful effect of the alkylated side chain was not as noticeable as expected [19,24]. The increase in
the inhibition of an IL with the increase of the alkylated side chain can only be observed sharply from the 4 carbons. This may explain the results obtained [33]. Since the difference between the EC\textsubscript{50} is very low, we can conclude that the length of the side chain of alkyl cations is significantly variable.

The influence of the cation and the anion on the inhibition of ILs seems to be independent, since the inhibition is the result of the sum of both impacts of cations and anions, not forgetting the external factors.

2.2. Evaluation of Ionic Liquids Active Pharmaceutical Ingredients (IL-APIs) Inhibition in Elastase Enzyme Activity

In the same conditions, we also tested several IL-APIs compounds. As it was explained before, ILs used as pharmaceuticals present new and unique properties compared to solid dosage forms.

So, in Table 2, we present the IL-APIs tested that present an inhibitory effect to elastase enzyme and the inhibition profiles of each one is represented graphically in Figure 2.

Table 2. Results of elastase inhibition by IL-APIs expressed as EC\textsubscript{50}.

| Ionic Liquid Active Pharmaceutical Ingredients (IL-APIs) | Molecular Weight (g mol\textsuperscript{-1}) | EC\textsubscript{50} (µM) ± SD (1) | Confidence Intervals |
|--------------------------------------------------------|--------------------------------------------|----------------------------------|---------------------|
| Lithium bistriflimide                                  | 287.1                                      | 209 ± 12                         | ±110                |
| 1-ethyl-3-methylimidazolium salicylate                 | 248.3                                      | 290 ± 86                         | ±774                |
| Benzethonium chloride                                 | 448.1                                      | 166 ± 4                          | ±40                 |
| Sodium salicylate *                                    | 160.1                                      | 124 ± 4                          | ±33                 |
| Benzalkonium salicylate                                | 452.8                                      | 230 ± 20                         | ±182                |
| Trihexyltetradecylphosphonium docusate                 | 905.4                                      | >700                             | -                   |
| Benzethonium salicylate                                | 549.7                                      | >500                             | -                   |
| Benzethonium docusate                                  | 834.2                                      | >200                             | -                   |
| Benzethonium bistriflimide                             | 692.8                                      | >1000                            | -                   |
| Tributylmethylphosphonium salicylate                  | 621.0                                      | >200                             | -                   |
| Trihexyltetradecylphosphonium chloride                 | 519.3                                      | >100                             | -                   |

(1) Standard deviation; * It is not an IL-API but a salt.

Considering Table 2 and comparing with ILs results, we can see that IL-APIs EC\textsubscript{50} are lower than ILs. So, it is necessary a lower concentration to obtain an inhibitory elastase enzyme effect using these IL-APIs.

The IL-API with lower EC\textsubscript{50} in elastase activity was sodium salicylate (124 ± 4 µM) and the IL-API that presents higher EC\textsubscript{50} value was benzethonium bistriflimide (>1000 µM).

To better understand the results obtained, an ANOVA statistic test was performed for all the IL-APIs that present salicylate anion in their chemical constitution (Figure 3).
Ionic Liquid Active Pharmaceutical Ingredients (IL-APIs) Molecular Weight (g mol\(^{-1}\))

| Compound                        | Molecular Weight | EC\(_{50}\) (µM) ± SD |
|---------------------------------|------------------|-----------------------|
| Trihexyltetradecylphosphonium  | 905.4            | > 700                 |
| docusate                        |                  |                       |
| Trihexyltetradecylphosphonium  | 519.3            | > 100                 |
| chloride                        |                  |                       |
| Tributylmethylphosphonium       | 621.0            | > 200                 |
| salicylate                      |                  |                       |
| Benzethonium bistriflimide      | 692.8            | > 1000                |
| Benzethonium chloride           | 448.1            | 166 ± 4               |
| Benzethonium docusate           | 834.2            | > 200                 |
| Benzethonium chloride           | 248.3            | 230 ± 20              |
| Lithium bistriflimide           | 287.1            | 209 ± 12              |
| 1-ethyl-3-methylimidazolium     | 160.1            | 124 ± 4               |
| salicylate *                    |                  |                       |

To better understand the results obtained, an ANOVA statistic test was conducted. Considering Table 2 and comparing with ILs results, we can see that IL-APIs EC\(_{50}\) are lower than ILs. So, it is necessary a lower concentration to obtain an inhibitory effect on elastase (124 ± 4; 166 ± 4) and carboxylesterase (116.99 ± 0.02; 123.70 ± 0.009) enzymes, respectively.

Figure 2. Inhibition profiles of IL-APIs in elastase assays. Subtitles: • Lithium bistriflimide; * Benzaalkonium salicylate; ■ Sodium salicylate; × 1-ethyl-3-methylimidazolium salicylate; ▪ Benzethonium chloride.

Figure 3. ANOVA statistic test for salicylate anion IL-APIs.
According to Figure 3, it is possible to verify that sodium salicylate (raw material) is more toxic than the IL-APIs with the same anion. According to the EC$_{50}$ values (sodium salicylate EC$_{50}$ = 124 µM, 1-ethyl-3-methylimidazolium salicylate EC$_{50}$ = 290 µM and benzalkonium salicylate EC$_{50}$ = 230 µM), 1-ethyl-3-methylimidazolium salicylate and benzalkonium salicylate are 2.3 and 1.8 times less toxic than sodium salicylate, respectively. As stated by ANOVA statistic test, even with these differences in EC$_{50}$ values of these three compounds, there are no significant differences between them ($p > 0.05$).

The bistriflimide anion reduces the inhibition of the IL-APIs when combined with benzethonium and phosphonium cations when compared with the corresponding starting materials incorporating the chloride anion. These results are supported by the previous report, where it is suggested that the cation type combined with bistriflimide anion can circumvent its negative effect and in some cases the IL inhibition can be reduced [34].

In a pharmaceutical perspective, salicylate IL-APIs with distinct cations present antiseptic and antibacterial activity, namely benzalkonium (only the 1-ethyl-3-methylimidazolium cation is neutral), combined with the salicylate anion, with well recognized analgesic and antipyretic activity [35]. So, as sodium salicylate presents a lower EC$_{50}$, it could present a higher inhibition for elastase enzyme and at the same time an analgesic effect.

To better understand the action of IL-APIs in elastase, we compare the EC$_{50}$ values obtained for carboxylesterase (other enzyme) and V. fischeri (a microorganism) [36].

Comparing the values obtained, we can see that 1-ethyl-3-methylimidazolium salicylate is the only IL-API that the EC$_{50}$ is lower for elastase than for carboxylesterase and V. fischeri is. So, this IL-API presents a higher toxicity for elastase than in carboxylesterase and V. fischeri.

When we compare the EC$_{50}$ values of sodium salicylate and benzethonium chloride for elastase (124 ± 4; 166 ± 4) and carboxylesterase (116.99 ± 0.02; 123.700 ± 0.009) enzymes, we can conclude that the inhibition effect is similar for them, because the EC$_{50}$ values are also resemble.

On the other hand, the other IL-APIs that were tested in elastase, carboxylesterase and V. fischeri activity (benzalkonium salicylate, trihexyltetradecylphosphonium docusate, benzethonium salicylate, benzethonium docusate, benzethonium bistriflimide, and trihexyltetradecylphosphonium chloride) the EC$_{50}$ values obtained for elastase are higher than for carboxylesterase and V. fischeri [36].

As in ILs, the K$_{ow}$ is an important parameter to evaluate the inhibition of IL-APIs. In literature, there are already some K$_{ow}$ defined for some IL-APIs. Pinto et al. determined the partitioning properties of some salicylate IL-APIs [Cetylpyridinium salicylate (CetPySal), benzethonium salicylate (BeSal) and 1-ethyl-3-methylimidazolium salicylate (emimSal)] by the calculation of partition coefficients (K$_{ow}$), by derivative spectroscopy, using the K$_{p}$ calculator. All the tested IL-APIs present higher partition between the aqueous and lipid phases. This is confirmed by the significant increase of the K$_{p}$ values compared with the corresponding starting materials (sodium salicylate (NaSal), cetylpyridinium chloride (CetPyCl), benzethonium chloride (BeCl), 1-ethyl-3-methylimidazolium chloride (emim Cl)) that incorporate either the anion or the cation of each IL-APIs. The obtained K$_{p}$ values were up to about 6 times higher than those of the corresponding anions or cations [35].

As a positive control, it was tested a potent HNE inhibitor named MeOSuc-Ala-Ala-Pro-Val-chloromethylketone. The EC$_{50}$ value obtained was 0.47 mM ± 0.05. Comparing this compound with the others tested, we can conclude that the HNE inhibitor presents a lower EC$_{50}$ for elastase than all ILs and higher than IL-APIs.

3. Materials and Methods

3.1. Reagents

All solutions were prepared using ultrapure water from a Milli-Q water plus system with specific conductivity of less than 0.1 µS cm$^{-1}$ and the chemicals of analytical grade.
Elastase from porcine pancreas, N-Succinyl-Ala-Ala-Ala-p-nitroanilide, HEPES sodium salt, sodium acetate, sodium hydroxide and acetic acid were purchase to Sigma-Aldrich® (St. Louis, Missouri, United States). Sodium chloride and dimethyl sulfoxide (DMSO) were purchase to Merck® (Darmstadt, Germany) and Uvasol® (Darmstadt, Germany), respectively.

A HEPES buffer solution 0.1 M with sodium chloride (NaCl) 0.5 M at pH 7.5 was used to dissolve the reagents. The buffer solution was prepared weighting 14.6 g of sodium chloride and 12.4g of HEPES and dissolving in about 150 mL of water. The pH 7.5 was adjusted with a 1 M NaOH solution, and final volume was adjusted to 500 mL. A sodium acetate buffer (pH 5.5) solution was used to dissolve the enzyme. The buffer solution was prepared weighting 1.64 g of sodium acetate and dissolving in about 50 mL of water. The pH 5.5 was adjusted with a 17.4 M acetic acid solution, and final volume was adjusted to 100 mL.

All the enzyme elastase porcine was reconstituted by stock solution of 1 U mL$^{-1}$ using 2.5 mg of powder enzyme in 20 mL of sodium acetate buffer (pH 5.5). The stock solution was divided into 14 eppendorfs with a total volume of 1.43 mL per eppendorf. The eppendorfs were frozen.

A solution of N-Succinyl-Ala-Ala-Ala-p-nitroanilide was prepared daily dissolving 11.25 mg of substrate in 10 mL of DMSO.

For enzyme inhibition assays the aqueous solutions of: 1-Butyl-3-methylimidazolium tetrafluoroborate (bmim [BF$_4$]), 1-Butyl-3-methylimidazolium chloride (bmim [Cl]), 1-Ethyl-3-methylimidazolium tetrafluoroborate (emim [BF$_4$]), 1-Ethyl-3-methylimidazolium trifluoromethanesulfonate (emim [TfMs]), 1-Butyl-1-methylpyrrolidinium chloride (bmpyr [Cl]), 1-Butyl-4-methylpyridinium tetrafluoroborate (bmpy (BF$_4$)), Tetrabutylammonium chloride (tba (Cl)), Tetrabutylammonium acetate (tba (Ac)), Tetrabutylphosphonium methanesulfonate (tbph (ms)), 1-Butyl-3-methylimidazoliumacetate (bmim (Ac)), were prepared daily. ILs were purchased from Sigma-Aldrich® and kept in anhydrous environment.

The ionic liquids active pharmaceutical ingredients (ILs-APIs) were synthesized according to [35,36] and the aqueous solutions of lithium bistriflimide, 1-ethyl-3-methylimidazolium salicylate, benzethonium chloride, sodium salicylate, benzalkonium salicylate, trihexyltetradecylphosphonium docusate, benzethonium docusate, benzethonium bistriflimide, tributylmethylphosphonium salicylate, and trihexyltetradecylphosphonium chloride.

The chemical structures of all ILs and IL-APIs are presented in Supplementary Materials.

The HNE inhibitor named MeOSuc-Ala-Ala-Pro-Val-chloromethylketone was purchased from BioVision® (San Francisco Bay).

3.2. Apparatus

Absorbance measurements were performed on a Jasco® V-660 dual-beam spectrophotometer (Hachioji-shi, Tokyo) between 220 and 500 nm using 1 cm optical path quartz cells.

3.3. Optimization of Elastase Porcine Reaction

There is often a variety of different assays methods available for an enzyme. Taking this into account, there are some assays methods for elastase. So, the methodology developed in this work was based on the protocols described by Schulz-Fincke et al. and Ferreira et al. [9,37].

However, some optimization was done using the univariant method, which consists of changing, within a certain interval, the parameter to be optimized keeping the remaining parameters fixed. First, some physical and chemical factors that affect the reaction development were evaluated.

The pH of the reaction medium is an extremely important factor in the case of enzymatic reactions, directly influencing the sensitivity of the reaction. Also, changes in pH change the shape of the enzyme active site. Each enzyme has an optimal acting pH, where
its activity is maximum. So, HEPES buffer at pH 7.5 was used to ensure that the pH was controlled during the reaction.

For the optimization it was keep a substrate volume (10 µL) fixed in all assays, changing only its concentration. Regarding the enzyme, once it was reconstituted, changing the volume we put in each eppendorf also changed its concentration, with 1 U (units) of enzyme (concentration) corresponding to 1.43 mL of the volume of the enzyme.

The optimized parameters comprised the temperature, reaction time, substrate concentration and enzyme concentration and volume (Table 3).

| Parameter Tested  | Range                        | Selected Values |
|-------------------|------------------------------|-----------------|
| Temperature       | 25 °C and 37 °C              | 37 °C           |
| Reaction time     | 10 min, 15 min and 20 min    | 10 min          |
| Substrate concn.  | 50 µM, 60 µM, 75 µM, 100 µM and 150 µM | 100 µM         |
| Enzyme concn.     | 12.5 µL, 20 µL, 30 µL and 50 µL | 30 µL           |
| Enzyme volume     | 0.0874 U; 0.0139 U; 0.0209 U and 0.0349 U | 0.0209 U       |

The temperature is an important parameter to consider during an enzymatic reaction, as each enzyme has its optimal temperature which when exceeded can cause it to be inactive or changes in its active center. Moreover, the temperature effect on enzyme activity has been defined by two well-proved thermal parameters: the Arrhenius activity energy, which consists in the temperature effect on the catalytic rate constant (k_{cat}); and thermal stability, which defines the temperature effect on the thermal inactivation rate constant (k_{inact}) [38]. For elastase, it was fixed at 37 °C where higher absorbance signal was obtained.

Regarding the reaction time, 10, 15, and 20 min were evaluated. For 20 min, when we increased the enzyme concentration, the absorbance remains the same. This means that the substrate has already been completely converted into the product after 20 min, regardless the enzyme concentration used. On the other hand, for 10 and 15 min, we can saw that the absorbances are similar. So, as a compromise between sensitivity and the sampling rate, the reaction time selected was 10 min.

Regarding substrate concentration, it was tested three different concentrations: 50 µM, 75 µM and 100 µM. When the substrate concentration has been increased from 50 µM to 100 µM, the absorbance has also doubled (0.2 UA to 0.5 UA). So, the substrate concentration selected was 100 µM, since it is favourable to have high absorbance values in order to calculate the percentage of inhibition in presence of ILs and ILs-APIs.

Regarding the enzyme concentration/volume, there is an increase in absorbance up to 30 µL of enzyme, from then on, between 30 µL and 50 µL the absorbance remained similar. Thus, considering the sensitivity–consumption ratio of reagents, it was decided to select as enzyme volume 30 µL of enzyme (corresponding to 0.0209 U), since it is still in a linear zone and with a high absorbance.

After all the parameters optimized, the calibration curve obtained was: A = (0.006 ± 0.117) C (µM) + (-0.090 ± 0.001); R² = 0.992 where A is the absorbance obtained in the assay and C is the concentration of substrate in µM, respectively, with 95% confidence limits for the intercept and slope. The detection limit was calculated using the absorbance corresponding to the ordinate value at the origin with the addition of three times the Sy/x, interpolating this value on the calibration curve. The detection limit obtained was 7.06 µM. The quantification limit was calculated through the absorbance corresponding to the ordinate value at the origin plus ten times the Sy/x, interpolating this value on the calibration curve. The limit of quantification obtained was 23.54 µM.

3.4. Optimized Batch Procedure

After all the optimization, the final batch procedure was defined.
All the reagents (HEPES buffer, N-succinyl-Ala-Ala-Ala p-nitroanilide, Elastase and acetate buffer) were added sequentially in eppendorf, being the final volume equal to 250 µL. So, in each eppendorf it was added 137.5 µL of HEPES buffer, 10 µL of N-succinyl-Ala-Ala-Ala p-nitroanilide substrate, 30 µL of elastase, 70 µL of acetate buffer, 2.5 µL of DMSO. In inhibitory assays was 87.5 µL of HEPES buffer, 10 µL of N-succinyl-Ala-Ala-Ala p-nitroanilide substrate, 30 µL of elastase, 70 µL of acetate buffer, 2.5 µL of DMSO, and 50 µL of IL/IL-APIs.

Next, the eppendorf was placed inside the thermostatic bath at 37 °C for 10 min. After 10 min, the reaction product was measured in spectrophotometer at 405 nm.

3.5. Experimental Procedure

All assays were performed in batch mode. Thus, the different reagents were placed manually in an eppendorf at the desired concentrations and volumes. After, they were placed in a thermostatic bath where the reaction temperature was regulated for the desired period. The succinyl-Ala-Ala-Ala and p-nitroaniline result from the cleavage of the substrate N-succinyl-Ala-Ala-Ala-p-nitroaniline by porcine elastase enzyme. The enzyme activity was determined by monitoring the chromogenic compound, p-nitroaniline, at 405 nm. All results of ILs and IL-APIs were obtained in duplicate.

4. Conclusions

The development of strategies that allow obtaining new effective chemical compounds that bring advantages in their application has been the focus of the pharmaceutical industry. As such, the use of ILs in pharmaceutical applications has been an area of great interest in recent years due to its advantageous characteristics and properties. The selection of organic cations and biocompatible organic/inorganic anions has been referred to as a possibility for producing non-toxic ILs with advantages over other solvents.

Through this experimental work it was possible to evaluate the inhibition of several ILs and IL-APIs in the inhibition of the activity of elastase enzyme.

The results obtained can be a good contribution with regard to the impact of ILs and IL-APIs in humans. Since there are an elastase human enzyme, with high activity in several diseases and found since the beginning of the infection, its inhibition means the reduction of infection/inflammation and/or treatment of diseases. In this way, the objective is to find solvents, in this case ILs that are slightly toxic to the organism and relatively toxic to the enzyme so that they inhibit its activity, being able to act with antimicrobial effect in wounds.

EC50 values of 176 ± 4 mM to 289 ± 11 mM were obtained, with the most toxic IL for the enzyme elastase being tetrabutylammonium acetate and the least toxic was 1-butyl-3-methylimidazolium acetate. In general, a preferential enzymatic inhibition by the BF4 anion and containing pyrrolidinium and imidazole groups was observed for the ILs studied, with the pyrrolidinium group inhibiting the enzyme with EC50 values as low as 193.8 ± 0.6 mM. On the other hand, the methanesulfonate and trifluoromethanesulfonate and phosphonium groups had less negative effect on enzyme activity.

Moreover, the results showed that the structure of the ILs influences their toxicity, that is, the composition of the cation, the alkyl side chains and the anions. These results can be justified by considerations of structure-activity relationship.

With regard to IL-APIs with antimicrobial effect, we can conclude that sodium salicylate present a lower EC50 and benzethonium bistrihalide the higher EC50, when compared with all the IL-APIs tested in this study.

MeOSuc-Ala-Ala-Pro-Val-chloromethylketone, a positive control of the inhibition of enzyme activity was also tested, and comparing with IL-APIs tested those have even higher potential to inhibit the enzyme and consequently present a possibility of contributing to the decrease of wound infection.

The results obtained in this work provide significant information about the safety of the studied IL-APIs and must be combined in a more extensive analysis when more
information about the biological behavior is available. However, these approaches can be considered valuable screening assays, and from this perspective, the results may contribute to the decision of including these compounds in a higher stage of drug development.

**Supplementary Materials:** The following are available online. Figure S1: Chemical structures of the studied ILs. 1: 1-butyl-3-methylimidazolium tetrafluoroborate (bmim [BF₄]); 2: 1-ethyl-3-methylimidazolium tetrafluoroborate (emim [BF₄]); 3: 1-butyl-3-methylimidazolium acetate (bmim [Ac]); 4: 1-butyl-4-methylpyridinium tetrafluoroborate (bmpy [BF₄]); 5: 1-butyl-3-methylimidazolium chloride (bmim [Cl]); 6: 1-ethyl-3-methylimidazolium trifluoromethanesulfonate (emim [TfMs]); 7: 1-butyl-1-methylpyrrolidiniumchloride (bmpyr [Cl]); 8: tetrabutylphosphonium methanesulfonate (tbph [Ms]); 9: tetrabuthylammonium chloride (tba [Cl]); 10: tetrabutylammonium acetate (tba [Ac]); Figure S2: Chemical structures of the studied IL-APIs. 1: Benzethonium docusate; 2: benzethonium salicylate; 3: Lithium bistriflimide; 4: benzethonium bistriflimide; 5: 1-ethyl-3-methylimidazolium salicylate; 6: benzethonium chloride; 7: sodium salicylate; 8: benzalkonium salicylate; 9: trihexyltetradecylphosphonium docusate; 10: trihexyltetradecylphosphonium chloride; 11: tributylmethylphosphonium salicylate. * n = 8, 10, 12, 14, 16, 18.

**Author Contributions:** Conceptualization and methodology, S.A.P.; F.A.R.M., and M.L.M.F.S.S.; spectrophotometric measurements, F.A.R.M.; statistical methodology, S.A.P.; manuscript preparation, S.A.P. and F.A.R.M.; manuscript review: A.R.T.S.A. and M.L.M.F.S.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work received financial support from the European Union (FEDER funds POCI/01/0145/FEDER/007265) and National Funds (FCT/MEC, Fundação para a Ciência e Tecnologia and Ministério da Educação e Ciência) under the Partnership Agreement PT2020 UID/QUI/50006/2013. Also by POCI-01-0145-FEDER-030163, financed by FEDER-Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020-Operational Programme for Competitiveness and Internationalization (POCI), Portugal 2020. Sarah A. P. Pereira received a PhD Grant (SFRH/BD/138835/2018) from FCT.

**Data Availability Statement:** Data is contained within the article or supplementary material. The data presented in this study are available in this manuscript.

**Acknowledgments:** The authors thank Katharina Schröder from TU Wien, Institute of Applied Synthetic Chemistry in Vienna for the synthesis of IL-APIs tested.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Sample Availability:** All ILs were purchased from Sigma-Aldrich® and IL-APIs compounds were synthesized by Katharina Schröder.

**References**

1. Hasmann, A.; Gewessler, U.; Hulla, E.; Schneider, K.P.; Binder, B.; Francesko, A.; Tzanov, T.; Schintler, M.; Van der Palen, J.; Guebitz, G.M.; et al. Sensor materials for the detection of human neutrophil elastase and cathepsin G activity in wound fluid. *Exp. Dermatol.* **2011**, *20*, 508–513. [CrossRef] [PubMed]

2. von Nussbaum, F.; Li, V. Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores. *Bioorganic. Med. Chem. Lett.* **2015**, *25*, 4370–4381. [CrossRef] [PubMed]

3. Korkmaz, B.; Horwitz, M.S.; Jenne, D.E.; Gauthier, F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. *Pharm. Rev.* **2010**, *62*, 726–759. [CrossRef] [PubMed]

4. Lucas, S.D.; Costa, E.; Guedes, R.C.; Moreira, R. Targeting COPD: Advances on low-molecular-weight inhibitors of human neutrophil elastase. *Med. Res. Rev.* **2013**, *33*, E73–E101. [CrossRef]

5. Kafienah, W.; Buttle, D.J.; Burnett, D.; Hollander, A.P. Cleavage of native type I collagen by human neutrophil elastase. *Biochem. J.* **1998**, *330 Pt 2*, 897–902. [CrossRef]

6. Tsaka, T.; Herkner, K.R. Polymorphonuclear elastase in neonatal sepsis. *Clin. Chim. Acta* **1990**, *193*, 103–111. [CrossRef]

7. Peters, K.M.; Koberg, K.; Rosendahl, T.; Haubeck, H.D. PMN elastase in bone and joint infections. *Int. Orthop.* **1994**, *18*, 352–355. [CrossRef]

8. Diegelmann, R.; Evans, M. Wound Healing: An Overview of Acute, Fibrotic and Delayed Healing. *Front. Biosci. J. Virtual Libr.* **2004**, *9*, 283–289. [CrossRef]

9. Ferreira, A.V.; Perelshtein, I.; Perkas, N.; Gedanken, A.; Cunha, J.; Cavaco-Paulo, A. Detection of human neutrophil elastase (HNE) on wound dressings as marker of inflammation. *Appl. Microbiol. Biotechnol.* **2017**, *101*, 1443–1454. [CrossRef]
10. Lv, X.; Chen, K.; Shi, G.; Lin, W.; Bai, H.; Li, H.; Tang, G.; Wang, C. Design and tuning of intramolecular hydrogen bond for efficient inhibition of tumor growth. *Sci. Adv.* 2020, 6, eabb7788. [CrossRef]

11. Zhao, H. Methods for stabilizing and activating enzymes in ionic liquids—A review. *J. Chem. Technol. Biotechnol.* 2010, 85, 891–907. [CrossRef]

12. Hough, W.L.; Smiglak, H.; Rodríguez, H.; Swatloski, R.P.; Speer, S.K.; Daly, D.T.; Pernak, J.; Grisel, J.E.; Carliss, R.D.; Soutullo, M.D.; et al. The third evolution of ionic liquids: Active pharmaceutical ingredients. *New J. Chem.* 2007, 31, 1429–1436. [CrossRef]

13. Shamshina, J.L.; Kelley, S.P.; Gurau, G.; Rogers, R.D. Chemistry: Develop ionic liquid drugs. *Nature* 2015, 528, 188–189. [CrossRef] [PubMed]

14. Bica, K.; Rogers, R.D. Confused ionic liquid ions—a “liquification” and dosage strategy for pharmaceutically active salts. *Chem. Commun.* 2010, 46, 1215–1217. [CrossRef]

15. Steimenovski, J.; MacFarlane, D.R.; Bica, K.; Rogers, R.D. Crystalline vs. Ionic Liquid Salt Forms of Active Pharmaceutical Ingredients: A Position Paper. *Pharm. Res.* 2010, 27, 521–526. [CrossRef]

16. Ferraz, R.; Branco, L.C.; Marrucho, I.M.; Araújo, J.M.M.; Rebelo, L.P.N.; da Ponte, M.N.; Prudêncio, C.; Noronha, J.P.; Petrovski, Z. Development of novel ionic liquids based on ampicillin. *MedChemComm* 2013, 4, 493–497. [CrossRef]

17. Bica, K.; Rijksen, C.; Nieuwenhuyzen, M.; Rogers, R.D. In search of pure liquid salt forms of aspirin: Ionic liquid approaches with acetylsalicylic acid and salicylic acid. *Phys. Chem. Chem. Phys.* 2010, 12, 2011–2017. [CrossRef]

18. Bode, W.; Meyer, E., Jr.; Powers, J.C. Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors. *Biochemistry* 1999, 28, 1951–1963. [CrossRef]

19. Egorova, K.S.; Ananikov, V.P. Toxicity of Ionic Liquids: Eco(cyto)activity as Complicated, but Unavoidable Parameter for Task-Specific Optimization. *ChemSusChem* 2014, 7, 336–360. [CrossRef]

20. Dong, X.; Fan, Y.; Zhang, H.; Zhong, Y.; Yang, Y.; Miao, J.; Hua, S. Inhibitory effects of ionic liquids on the lactic dehydrogenase activity. *Int. J. Biol. Macromol.* 2016, 86, 155–161. [CrossRef]

21. Fan, Y.; Dong, X.; Li, X.; Zhong, Y.; Kong, J.; Hua, S.; Miao, J.; Li, Y. Spectroscopic studies on the inhibitory effects of ionic liquids on lipase activity. *Spectrochim. Acta A Mol. Biomol. Spectros.* 2016, 159, 128–133. [CrossRef] [PubMed]

22. Cvjetko Bubalo, M.; Radošević, K.; Gaurina Sršek, V.; Das, R.N.; Popelier, P.; Roy, K. Cytotoxicity towards CCO cells of ionic liquid approaches with acetylsalicylic acid and salicylic acid. *Phys. Chem. Chem. Phys.* 2010, 12, 2011–2017. [CrossRef]

23. Naushad, M.; Alothman, Z.A.; Khan, A.B.; Ali, M. Effect of ionic liquid on activity, stability, and structure of enzymes: A review. *Int. J. Biol. Macromol.* 2012, 51, 555–560. [CrossRef] [PubMed]

24. Azevedo, A.M.O.; Pereira, S.A.P.; Passos, M.L.C.; Costa, S.P.F.; Pinto, P.C.A.G.; Araujo, A.R.T.S.; Saraiva, M.L.M.F.S. Assessment of ionic liquids’ toxicity through the inhibition of acylase I activity on a microflow system. *Chemosphere* 2017, 173, 351–358. [CrossRef]

25. Costa, S.P.F.; Martins, B.S.F.; Pinto, P.C.A.G.; Saraiva, M.L.M.F.S. Automated cytochrome c oxidase bioassay developed for ionic liquids’ toxicity assessment. *J. Hazard. Mater.* 2016, 309, 165–172. [CrossRef]

26. Gao, W.-W.; Zhang, F.-X.; Zhang, G.-X.; Zhou, C.-H. Key factors affecting the activity and stability of enzymes in ionic liquids and novel applications in biocatalysis. *Biochim. Biophys. Acta.* 2015, 1855, 67–84. [CrossRef]

27. Ventura, S.P.M.; Gonçalves, A.M.M.; Sintra, T.; Pereira, J.L.; Gonçalves, F.; Coutinho, J.A.P. Designing ionic liquids: The chemical structure role in the toxicity. *Ecotoxicol. Environ. Saf.* 2015, 112, 22–28. [CrossRef] [PubMed]

28. Arning, J.; Stolte, S.; Bösen, A.; Stock, F.; Pintner, W.R.; Welz-Biermann, U.; Jastorff, B.; Ranke, J. Qualitative and quantitative structure activity relationships for the inhibitory effects of cationic head groups, functionalised side chains and anions of ionic liquids. *Chemosphere* 2013, 28, 22–28. [CrossRef] [PubMed]

29. Naushad, M.; Alothman, Z.A.; Khan, A.B.; Ali, M. Effect of ionic liquid on activity, stability, and structure of enzymes: A review. *Int. J. Biol. Macromol.* 2012, 51, 555–560. [CrossRef] [PubMed]

30. Docherty, K.M.; Kulpa, J.C.F. Toxicity and antimicrobial activity of imidazolium and pyridinium ionic liquids. *J. Hazard. Mater.* 2010, 173, 1660–1665. [CrossRef]

31. Do et al., The third evolution of ionic liquids: Active pharmaceutical ingredients. *New J. Chem.* 2016, 39, 188–189. [CrossRef]

32. Arning, J.; Stolte, S.; Bösen, A.; Stock, F.; Pintner, W.R.; Welz-Biermann, U.; Jastorff, B.; Ranke, J. Qualitative and quantitative structure activity relationships for the inhibitory effects of cationic head groups, functionalised side chains and anions of ionic liquids on acetylicholinesterase. *Chemosphere* 2008, 70, 47–58. [CrossRef]

33. Arning, J.; Stolte, S.; Bösen, A.; Stock, F.; Pintner, W.R.; Welz-Biermann, U.; Jastorff, B.; Ranke, J. Qualitative and quantitative structure activity relationships for the inhibitory effects of cationic head groups, functionalised side chains and anions of ionic liquids on acetylicholinesterase. *Chemosphere* 2008, 70, 47–58. [CrossRef]

34. Frade, R.F.M.; Rosatella, A.A.; Marques, C.S.; Branco, L.C.; Kulkarni, P.S.; Mateus, N.M.M.; Afonso, C.A.M.; Duarte, C.M.M. Designing ionic liquids: The chemical structure role in the toxicity. *Ecotoxicol. Environ. Saf.* 2013, 22, 1–12. [CrossRef]

35. Arming, J.; Stolte, S.; Bösen, A.; Stock, F.; Pintner, W.R.; Welz-Biermann, U.; Jastorff, B.; Ranke, J. Qualitative and quantitative structure activity relationships for the inhibitory effects of cationic head groups, functionalised side chains and anions of ionic liquids on acetylicholinesterase. *Chemosphere* 2008, 70, 47–58. [CrossRef]

36. Stock, F.; Hoffmann, J.; Ranke, J.; Stoermann, R.; Ondruschka, B.; Jastorff, B. Effects of Ionic Liquids on the Acetylcholinesterase—A Structure-Activity Relationship Consideration. *Chem. Rev.* 2004, 104, 286–290. [CrossRef]
37. Schulz-Fincke, A.C.; Tikhomirov, A.S.; Braune, A.; Girbl, T.; Gilberg, E.; Bajorath, J.; Blaut, M.; Nourshargh, S.; Gütschow, M. Design of an Activity-Based Probe for Human Neutrophil Elastase: Implementation of the Lossen Rearrangement To Induce Förster Resonance Energy Transfers. *Biochemistry* 2018, 57, 742–752. [CrossRef]

38. Peterson, M.E.; Daniel, R.M.; Danson, M.J.; Eisenthal, R. The dependence of enzyme activity on temperature: Determination and validation of parameters. *Biochem. J.* 2007, 402, 331–337. [CrossRef]